NCT04109326 (APAD2) is a NA clinical trial of APAD in Breast Cancer, sponsored by Institut du Cancer de Montpellier - Val d'Aurelle.

Who is sponsoring NCT04109326?

NCT04109326 is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle.

What drugs are being tested in NCT04109326?

Interventions in NCT04109326: APAD.

What condition does NCT04109326 study?

NCT04109326 studies Breast Cancer.

Is NCT04109326 still recruiting?

NCT04109326 is currently completed. Last updated 30 September 2019.

Last reviewed 2019-09-30 · How we verify

NCT04109326: APAD2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of a Program of Physical Activity and Nutritional Therapeutic Education in Breast Cancer Patients

Completed NA Last updated 30 September 2019

What this trial tests

NA trial testing APAD in Breast Cancer in 360 participants. Completed in 11 June 2016.

Timeline

15 May 2013

Primary endpoint
5 January 2016

11 June 2016

Quick facts

Lead sponsor	Institut du Cancer de Montpellier - Val d'Aurelle
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	360
Start date	15 May 2013
Primary completion	5 January 2016
Estimated completion	11 June 2016
Sites	8 locations across France

Drugs / interventions tested

APAD

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Institut du Cancer de Montpellier - Val d'Aurelle — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multicenter randomized controlled trial aims to evaluate the effect of a tailored program of physical activity and nutritional therapeutic education on clinical, psychological and sociological factors in breast cancer patients undergoing adjuvant treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial.
Jacot W, Arnaud A, Jarlier M, Lefeuvre-Plesse C, et al · · 2020 · cited 24× · PMID 33050321 · DOI 10.3390/nu12103081
Feasibility evaluation of a virtual lifestyle intervention for early-stage breast cancer survivors undergoing chemotherapy.
Tan SYC, Addo IY, Collett G, Price E, et al · · 2026 · cited 1× · PMID 41619795 · DOI 10.1093/jncics/pkaf122

Verify or expand the search:

Other trials of APAD

Trials testing the same drug.

NCT04204070 — Accuro and the Use of Real Time Ultra Sound With Acoustic Puncture Assisted Device to Confirm Epidural Space End Point · NA · unknown

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Institut du Cancer de Montpellier - Val d'Aurelle trials

Trials by the same sponsor.

NCT07523152 — Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With H · NA · not yet recruiting
NCT07198971 — Feasibility Study Incorporating Music Therapy to Optimise the Smoking Cessation Process Coordinated by a Tobacco Addicti · NA · recruiting
NCT07043543 — Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11) · NA · not yet recruiting
NCT07441941 — Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup · recruiting
NCT06382818 — Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04109326 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut du Cancer de Montpellier - Val d'Aurelle
Last refreshed: 30 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04109326.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing